Investigational Drug Development

Looking Forward

Fujifilm is conducting research to study the potential of new drugs to address unmet medical needs, focusing on cancer, infectious diseases and central nervous system diseases.

Fujifilm currently has clinical trials in the United States for influenza, cancer, Alzheimer’s disease and COVID-19. These clinical trials are underway in collaboration with various institutions throughout the country.

In 2016, Fujifilm provided the anti-influenza drug favipiravir (T-705) to the Guinean Government, as one of the supplies procured by the Japanese government’s emergency grant aid to counter the outbreak of Ebola Virus disease.

*Avigan Tablet has not been approved by the FDA for use in the USA

 

Investigational drug pipeline

The medicinal drugs under development by direct or indirect affiliates of FUJIFILM Holdings Corporation that are referred to on this page are not approved for marketing and sale in the European Union and the USA.

Partnership Strategy

We are seeking the following partners:

• Companies interested in clinical development and commercialization of Fujifilm’s pipeline drugs.
• Companies willing to provide immune checkpoint inhibitors for, and/or co-sponsor clinical development of, combination therapies with Fujifilm liposomal drugs (FF-10832 and FF-10850).